Lyndra Therapeutics Revenue and Competitors

Boston, MA USA

Location

$163.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Lyndra Therapeutics's estimated annual revenue is currently $17.2M per year.(i)
  • Lyndra Therapeutics's estimated revenue per employee is $155,000
  • Lyndra Therapeutics's total funding is $163.3M.

Employee Data

  • Lyndra Therapeutics has 111 Employees.(i)
  • Lyndra Therapeutics grew their employee count by -38% last year.

Lyndra Therapeutics's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
Chief Technology OfficerReveal Email/Phone
3
Chief Staff & Head Government Affairs/Corporate DevelopmentReveal Email/Phone
4
VP Engineering and IndustrializationReveal Email/Phone
5
VP Clinical DevelopmentReveal Email/Phone
6
SVP Portfolio and Commercial Strategy, Oral Weekly Risperidone Program LeaderReveal Email/Phone
7
VP, Technical OperationsReveal Email/Phone
8
VP Quality AssuranceReveal Email/Phone
9
SVP, Quality and ComplianceReveal Email/Phone
10
VP, Data Compliance & Information TechnologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Lyndra Therapeutics?

TRANSFORMING THE WAY WE TAKE MEDICINE FOR A HEALTHIER WORLD ULTRA-LONG-ACTING ORAL DOSING IS ACHIEVABLE Our Team has developed the first ultra-long-acting pill that lasts a week or longer and can provide a wide range of medicines in a familiar oral capsule form. Once inside the stomach, the capsule delivers steady amounts of medicine for seven days or more. Our once-weekly product has safely demonstrated gastric residence with predictable pharmacokinetics in humans. There are no other oral products which provide ultra-long-acting therapeutic coverage or a controlled, steady delivery of medicine which can reduce side effects and improve drug efficacy, resulting in measurable health outcomes. At Lyndra, we ask “What if we stopped trying to change the patient and changed the pill instead?"​ Want to learn more? Please visit our website or contact us at info@lyndra.com. INSPIRED to Join Our Team? Check us out and apply! www.lyndra.com/join-our-team/ At Lyndra Therapeutics, we are INSPIRED by team members who are excited by innovation and growth, demonstrate strong technical expertise, and live our values. We are looking for people who will bring fresh ideas based on experience and who lead by adapting to the fast pace of an emerging biotech. In preparation for Phase 2 clinical development, we are looking to build our team in key areas in the near term : Clinical, Medical, Pre-clinical, Formulation, Process Development, Mechanical Engineering, and Manufacturing.

keywords:N/A

$163.3M

Total Funding

111

Number of Employees

$17.2M

Revenue (est)

-38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lyndra Therapeutics News

2022-04-19 - Global Sustained Release Coating Market to Surpass US ...

In July 2019, Lyndra Therapeutics, a biopharmaceutical company, announced a partnership with Gilead Sciences, Inc., a biotechnology company,...

2022-04-17 - synthetic Hormones Market is rapidly expanding due to the ...

... of thyroid-related diseases worldwide and robust R&D activities | Pfizer Inc., McGuff Pharmaceuticals, Inc., Lyndra Therapeutics, Inc.

2022-03-30 - Alnylam's Greenstreet Takes Home $8.5M, Ex-CEO ...

... as well as chair of the board of SQZ Biotech, executive chair of Lyndra Therapeutics, and manages the LS Polaris Innovation Fund.

2021-06-27 - Lyndra Therapeutics Closes $60.5M Series C Financing

Lyndra Therapeutics, a Watertown, Mass.-based clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, closed a $60.5m Series C financing. The round was led by new investor, AIG Investments, an af ...

2021-06-24 - Lyndra Therapeutics : Completes $60.5 Million Series C Financing

Lyndra Therapeutics, a clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, today announced the closing of its $60.5 million Series C financing. The proceeds of the round, led by new investor, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$31.1M115-17%N/A
#2
N/A1162%N/A
#3
$23.5M11752%N/A
#4
$15M119-37%$217.5M
#5
$25.2M1206%N/A